Cantor Fitzgerald reaffirms Overweight rating on Vaxcyte

what happened

TradingView reports that Cantor Fitzgerald has reiterated its Overweight rating on Vaxcyte shares and maintained a $120.00 price target. The target represents implied upside of 68.1% from the stock’s Oct. 9 closing price of $71.38.

The analyst note said positive OPUS-1 results lifted the estimated probability of success for Vaxcyte’s adult vaccine candidates to 90%. Cantor Fitzgerald described the data as significantly de-risking the program, while noting that manufacturing and regulatory submission challenges remain ahead.

Pediatric phase 2 results expected within the next eight months could provide another catalyst for the shares. Favorable data could improve Vaxcyte’s valuation and risk profile, supporting the Overweight view.

Across the three most recent PCVX analyst notes published over the past 30 days, targets ranged from $89 to $125. BTIG reiterated Buy with an $89 target, Needham maintained Buy at $122, and Guggenheim maintained Buy at $125. Selected reference data was provided by Benzinga. This report is not investment advice.

why it matters

The update puts attention on OPUS-1’s 90% probability-of-success assessment and the next eight months of pediatric phase 2 data. Manufacturing and regulatory submission requirements remain the stated challenges for the program.

instruments